Update shared on01 Aug 2025
Fair value Decreased 5.85%Despite a sharp upward revision in revenue growth forecasts, a significant decline in net profit margin has led to a lower consensus analyst price target for uniQure, which has fallen from $35.51 to $33.44.
What's in the News
- uniQure filed a follow-on equity offering of $200 million through an at-the-market ordinary share issuance.
- Reached agreement with the FDA on key elements of the AMT-130 Huntington's disease gene therapy BLA submission, with a planned filing in the first quarter of 2026 and mapped regulatory milestones for 2025.
- Presented positive early data from the first participant in the Phase I/IIa trial of AMT-260 for refractory mesial temporal lobe epilepsy, showing reduced seizure frequency and no serious adverse events, with ongoing patient recruitment and additional sites planned.
Valuation Changes
Summary of Valuation Changes for uniQure
- The Consensus Analyst Price Target has fallen from $35.51 to $33.44.
- The Consensus Revenue Growth forecasts for uniQure has significantly risen from 147.5% per annum to 193.5% per annum.
- The Net Profit Margin for uniQure has significantly fallen from 10.54% to 8.68%.
Disclaimer
AnalystConsensusTarget is a tool utilizing a Large Language Model (LLM) that ingests data on consensus price targets, forecasted revenue and earnings figures, as well as the transcripts of earnings calls to produce qualitative analysis. The narratives produced by AnalystConsensusTarget are general in nature and are based solely on analyst data and publicly-available material published by the respective companies. These scenarios are not indicative of the company's future performance and are exploratory in nature. Simply Wall St has no position in the company(s) mentioned. Simply Wall St may provide the securities issuer or related entities with website advertising services for a fee, on an arm's length basis. These relationships have no impact on the way we conduct our business, the content we host, or how our content is served to users. The price targets and estimates used are consensus data, and do not constitute a recommendation to buy or sell any stock, and they do not take account of your objectives, or your financial situation. Note that AnalystConsensusTarget's analysis may not factor in the latest price-sensitive company announcements or qualitative material.